Impact of UK policy initiatives on use of medicines to aid smoking cessation
Impact of UK policy initiatives on use of medicines to aid smoking cessation
复制标题
DOI：
10.1136/tc.2004.008649
复制
发表时间：
2005-06-01
期刊：
影响因子：
5.2
通讯作者：
McNeill, A
中科院分区：
文献类型：
--
作者：
West, R;DiMarino, ME;McNeill, A
背景：增加有效戒烟辅助手段的使用原则上可以对公共卫生产生重大影响。英国政府采取了几项重大政策举措，试图增加戒烟药物的使用。重要的是要评估什么样的效果，如果有的话，这些都必须告知未来的政策，在英国和international.Objective：本研究使用的销售数据，以审查政府的举措，以增加获得戒烟medicines.Design的影响：有关处方和非处方药销售（1999-2002年）的信息。利用率的估计值与国家统计局（ONS）综合调查的结果进行了比较。通过时间序列分析评估了政策举措（使药品可报销并在药店外进行一般销售）的影响。此外，推出了一种新的尼古丁替代疗法（NRT）产品（尼古丁含片），这对总利用率的影响进行了assessment.Results：使安非他酮，随后尼古丁替代疗法（NRT），可报销的药物使用产生了重大影响，在每种情况下，估计增加超过80 000“治疗周”每月购买。此外，尼古丁含片的引入增加了总利用率，并没有减少其他药物的使用。根据销售和调查数据，吸烟者使用药物帮助戒烟的比例从1999年的8-9%增加到2002年的17%，翻了一番多。英国国家统计局的调查显示，尝试戒烟的吸烟者比例并未增加，因此其影响仅限于药物辅助戒烟的比例。结论：在英国，使戒烟药物可报销导致使用率大幅增加。虽然对吸烟流行率的影响太小，无法在国家调查中发现，但它可能对公共卫生产生重大影响。
Context: Increasing the use of effective smoking cessation aids could in principle have a substantial public health impact. The UK government has undertaken several major policy initiatives to try to increase usage of smoking cessation medicines. It is important to evaluate what effect, if any, these have had to inform future policy in the UK and internationally.Objective: This study used sales data to examine the impact of government initiatives to increase access to smoking cessation medicines.Design: Information about prescription and non-prescription sales ( 1999-2002) was obtained. Estimates of utilisation were compared with findings from the Office of National Statistics ( ONS) omnibus surveys. The effects of policy initiatives ( making the medicines reimbursable and making them available on general sale outside pharmacies) were assessed by means of time series analysis. In addition a new nicotine replacement therapy ( NRT) product ( a nicotine lozenge) was launched and the effect of this on total utilisation was assessed.Results: Making bupropion, and subsequently nicotine replacement therapy ( NRT), reimbursable had a major impact in medication usage; the estimated increase in each case was more than 80 000 "treatment weeks'' purchased per month. In addition, introduction of a nicotine lozenge increased total utilisation and did not detract from usage of other medicines. According to both the sales and the survey data, the proportion of smokers using medicines to aid smoking cessation more than doubled from 8-9% in 1999 to 17% in 2002. The ONS surveys showed no increase in the proportions of smokers making quit attempts and so the effects were solely on the proportions of quit attempts that were aided by medication.Conclusions: In the UK, making smoking cessation medicines reimbursable led to a large increase in utilisation. While the effect on smoking prevalence would be too small to be detected in national surveys it could have a substantial public health impact.